Aleniglipron
ACCESS II
Gasherbrum Bio, Inc · Phase 2 · Completed · Enrollment 85
Participants reaching threshold, %
Source: Cited trial source. The denominator is the source figure, when it states one.
No selected arm reports a responder percent.
Show as table
| Arm | ≥5% | ≥10% | ≥15% | ≥20% |
|---|---|---|---|---|
| Sentinel | n/r | n/r | n/r | n/r |
| Cohort 1a | n/r | n/r | n/r | n/r |
| Cohort 1b | n/r | n/r | n/r | n/r |
| Cohort 1c | n/r | n/r | n/r | n/r |
Not shown
- Sentinel: endpoint not reported
- Cohort 1a: endpoint not reported
- Cohort 1b: endpoint not reported
- Cohort 1c: endpoint not reported